Assoc. Prof. Alessandro Volpe

Prof. David Pfister

After finishing medical school in November 2004 I started my residency in the Department of Urology at the University of Cologne. For my endoscopic training I switched to the General Hospital in Weiden (Oberpfalz/Bavaria) between August 2006 and March 2007. After returning to Cologne I heightened my oncologic education under Prof. Heidenreich. The oncologic training consisted of two arms: medical and surgical oncology. In 2009 my education was augmented at the University Hospital of Aachen. In 2010 I passed my urologic board exam. Since 2011 I have been working as a staff urologist with main interests in castration resistant prostate cancer and testicular cancer. In 2011 I passed the Charles Huggins grant, an educational grant at the Center for Prostate Disease Research in Maryland, USA. In 2012 I received an additional qualification in the systemic treatment of solid tumors and since that time I have organised and led the urological clinical trial center. In 2012 I qualified as a Professor and became an Associate Professor in November 2012 for medical oncologic treatment in urological tumors. At the end of 2015 I became the Commissionary Leader of the Urologic Department of the University of Aachen. Since 2016 I have become the Deputy Director of the Department of Urology, Uro-oncology and Robot Assisted Surgery, University Hospital of Cologne. Special interest is castration resistant, radiation resistant prostate cancer and testicular cancer.

Dr. Daniel Keizman

Dr. Keizman is an expert in Genitourinary Oncology, particularly in prostate, bladder, kidney and testicular cancer; and at present serves as the head of the Genitourinary Oncology service at Tel-Aviv Sourasky Medical Center, Israel.

He graduated from The Sackler Faculty of Medicine, Tel Aviv University, and then completed his residency in Internal Medicine (at the Tel-Aviv Medical Center), Medical Oncology (at the Tel-Aviv Medical Center) and a Post Doctoral Clinical Fellowship in Genitourinary Oncology at the John Hopkins Hospital, Kimmel Cancer Center, Baltimore, USA.

He is the author of numerous studies and review articles published in medical journals, and a reviewer of numerous medical journals. He presented numerous studies in international meetings. His current research activity focuses on genitourinary oncology.

Assoc. Prof. Shilpa Gupta

Shilpa Gupta, MD is an Associate Professor in GU Oncology at the Cleveland Clinic, Ohio. Prior to this appointment, Dr. Gupta was the Associate Professor in the Division of Hematology, Oncology and Transplantation and the lead for the Phase 1 Interdisciplinary Solid Tumor Program at the Masonic Cancer Center, University of Minnesota, Minneapolis, USA. Before joining University of Minnesota in July 2015, Dr. Gupta was faculty in Genitourinary Oncology and Experimental Therapeutics at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida for 4 years. Dr. Gupta’s clinical and research interests are to treat patients with genitourinary malignancies and develop novel trials using targeted therapies and immunotherapies. She is currently the Principal investigator of several early and late phase trials in genitourinary oncology. Dr. Gupta is passionate about her research and has published her research across a variety of peer-reviewed journals and book chapters.

Dr. Tobias Klatte

Tobias Klatte is Consultant Urological Surgeon at the Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust. He is also a Visiting Researcher at the University of Cambridge and Honorary Lecturer at the University of Edinburgh. Dr Klatte obtained both his medical degree and doctoral degree at the University of Magdeburg, Germany. He received his clinical training at the Medical University of Vienna/Vienna General Hospital, and where he subsequently joined the faculty and rose to the rank of associate professor. He moved to the UK in 2017, where he spent one year at Addenbrooke’s Hospital in Cambridge before being appointed in Bournemouth. Dr Klatte completed a research fellowship in urological oncology at the University of California-Los Angeles. His research is focused on kidney cancer and urothelial cancer, and he has published widely in these fields. In 2012, he completed his habilitation on prognostic factors in renal cell carcinoma.

Dr. Lisa Derosa

Dr. Fabio Schutz

Dr. Schutz graduated from Parana Federal University and did his internal medicine residency at Hospital de Clinicas in Curitiba - PR, Brazil. Then, he moved to Sao Paulo - SP for his medical oncology clinical fellowship at Hospital Sirio Libanes. After finishing his medical oncology fellowship, he worked for a couple of years as an assistant medical oncologist in the same hospital. From 2009 to 2011, he worked as a research fellow in genitourinary (GU) oncology in the Lank Center for GU Oncology at the Dana-Farber Cancer Institute - Harvard Medical School in Boston - MA, USA. He developed several original research projects and authored many manuscripts in high impact journals. Since mid-2011, he is working as a medical oncologist of the BP - Beneficencia Portuguesa de Sao Paulo in Sao Paulo - SP, Brazil. He is most interested and is currently conducting clinical trials in GU cancers.

Dr. Tia Higano

Dr. Higano is a Professor in the Departments of Medicine (Division of Oncology) and Urology at the University of Washington and the University of British Columbia as well as a Member of the Clinical Division at Fred Hutchinson Cancer Research Center. She graduated from University of Massachusetts Medical School, finished internal medicine residency at Mayo Graduate School of Medicine, and completed hematology/oncology fellowship at University of Washington and Fred Hutchinson. Her research interests focus on new drug development including immunotherapy, the effects of androgen deprivation therapy on the male body and mind, and development of supportive care/survivorship programs for prostate cancer patients and their partners.

Dr. Gert Attard

Dr Attard is a Cancer Research UK Clinician Scientist and Team Leader at The Institute of Cancer Research and an Honorary Medical Oncology Consultant at the Royal Marsden NHS Foundation Trust, London, UK. He graduated with a degree in Medicine from the University of Malta in June 1999 and obtained a PhD in Medicine from the University of London (ICR) in 2010. His main research interest is dissecting treatment resistance, currently with a focus on plasma DNA analysis, in order to inform on the development of novel therapeutics and biomarkers for castration resistant prostate cancer (CRPC). He is an experienced clinical trialist in CRPC and a co-author of more than 100 peer-reviewed manuscripts, including several important papers on advanced prostate cancer. Dr Attard’s many awards over the years include the ASCO Foundation Annual Merit Award in 2007, Prostate Cancer Foundation Young Investor Award in 2008, the AACR-GlaxoSmithKline Outstanding Clinical Scholar Award in 2009, the Medical Research Society/Academy of Medical Sciences Sue McCarthy Prize in 2010 and the McElwain award in 2010. Dr Attard sits on a number of advisory boards and the editorial board of Annals of Oncology.

Dr. Yuji Miura

Prof. Neeraj Agarwal

Website: https://neerajagarwal.me/

Twitter: @neerajaiims

Neeraj Agarwal, MD

Associate Professor of Medicine,

Director, GU Medical Oncology, Division of Medical Oncology, Co-leader, Urologic Oncology Multidisciplinary Program, Huntsman Cancer Institute, University of Utah.

Address:
2000 Circle of Hope, Ste 2123,
Salt Lake City, Utah 84112
Phone: 801-585-0255
Fax: 801-585-0124

Prof. Evan Yu

Evan Y. Yu, M.D., is a medical oncologist specializing in prostate, bladder, and testicular cancer treatment and research.  He graduated Alpha Omega Alpha from the University of Washington School of Medicine and his post-doctoral training was at Harvard Medical School. He completed internal medicine residency at the Brigham and Women’s Hospital and oncology fellowship at the Dana-Farber Cancer Institute.  He returned to Seattle at the end of 2004 to join the faculty at the University of Washington and Fred Hutchinson Cancer Research Center. He now is a Full Professor, and he is the director of the Clinical Trials Core for GU malignancies, as well as having an integral role in the Pacific Northwest Prostate Cancer SPORE. His research focuses on testing the next wave of novel molecular targeted therapies and immunotherapy techniques, with a complementary focus on biomarkers. In addition to an active clinical and research practice, he also is the Assistant Fellowship Director and remains very active in student, resident, and fellow education. He has regularly been voted a “Top Doctor” by Castle Connolly, U.S. News and World Report, Seattle magazine, and Seattle Met magazine. He continues to serve on the National Cancer Institute Genitourinary Cancers Steering Committee.

Assoc. Prof. Martin Pichler

Martin Pichler obtained his MD at the Medical University of Graz in 2006, and his Master of Science in Molecular Biology at the Karl-Franzens University of Graz, Austria. Martin continued his cancer research training in different places, including The UT MD Anderson Cancer Center, Houston, USA (where he is Adjunct Faculty member at the Department of Experimental Therapeutics). He currently works as a medical oncologist with special focus on Urogential- and Gastrointestinal cancer, at the Division of Oncology, Medical University of Graz, Austria. He currently holds the research managing director position of this division and is the Head of the Research Unit for Non-Coding RNAs and Genome Editing in Cancer. His main research focus is to study molecular mechanisms of cancer biology, prognostic biomarker studies and clinical trials. He received several awards, grants and published about 170 peer-reviewed papers so far (https://forschung.medunigraz.at/fodok/suchen.person_uebersicht?sprache_in=en&ansicht_in=&menue_id_in=101&id_in=2001296) .

Dr. Neal Shore

Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr. Shore has conducted more than 250 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Bladder Cancer Advocacy Network,Society of Urologic Oncology Clinical Trials Consortium, Secretary-Treasurer, and is President, Large Urology Group Practice Association. He is a founder for both: CUSP Clinical Trials Consortium, as well as for DASHKO, large urology practices data registries. He serves as the National Urology Research Director for 21st Century Oncology. He has served on the AUA Male Health Committee; he is currently a member of the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank and the editorial boards of Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE(Academic Editor), Urology Practice,World Journal of Urology, and serves as Editor, Everyday Urology. He has more than 125 peer reviewed publications and numerous book chapters; he performs peer review for Lancet Oncology, European Urology,Journal Urology, Urology, BJUI,PCPD, and numerous other high impact scientific journals. A graduate of Duke University and Duke University Medical School, Dr. Shore completed a 6 month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.

Prof. Sandy Srinivas

Sandy Srinivas- Professor of Medicine/ Oncology- GU medical Oncologist - passionate about clinical trials and drug development and caring for patients with urologic cancers. Dr Srinivas has published extensively and is on national panels including the NCCN.

Assoc. Prof. Alicia Morgans

Dr. Morgans is an Associate Professor of Medicine in the Division of Hematology/Oncology at Northwestern University’s Robert H. Lurie Cancer Center where she serves as a genitourinary medical oncologist and outcomes researcher. She completed medical school and residency at the University of Pennsylvania School of Medicine, fellowship in Hematology/Oncology at Harvard’s Dana Farber Cancer Institute and Massachusetts General Hospital Cancer Center in Boston, and earned a Master of Public Health at Vanderbilt University. Dr. Morgans treats patients with prostate, bladder, and testicular cancer, and her research assesses complications of advanced prostate cancer survivorship and patient-centered treatment decision-making in advanced prostate cancer.

Assoc. Prof. Brian Costello

Brian A. Costello, M.D., M.S. is a Consultant in the Division of Medical Oncology at Mayo Clinic Rochester and is an Associate Professor of Oncology and Urology. He received his medical degree from the Medical College of Wisconsin and completed his internal medicine residency at the University of New Mexico School of Medicine. He then completed his medical oncology fellowship at Mayo Clinic. Dr. Costello was subsequently a Mayo Clinic Scholar during which time he focused on early phase clinical trials and genitourinary malignancies. Dr. Costello is currently the Chair of the Genitourinary Tumor Group of the Division of Medical Oncology at Mayo Clinic. He serves as a member of the NCCN Kidney Cancer Panel, the National Cancer Institute’s Renal Task Force, as well as the GU Cancers Core Committee of the Alliance for Clinical Trials in Oncology. He also previously served on the NCI Prostate Task Force from 2013 to 2016. He is actively involved in clinical and translational research and has a busy practice caring for patients with genitourinary cancers. Dr. Costello is actively involved in early drug development, especially in genitourinary malignancies. He is the Lead Investigator of the NCI-sponsored Mayo Phase II Program and is a member of the NCI’s Investigational Drug Steering Committee.

Assoc. Prof. Tanya Dorff

Following a residency at Mt. Sinai Hospital in New York City, Dr. Dorff came to LAC + USC Medical Center for her hematology and medical oncology fellowship. She currently heads the Genitourinary group within the Department of Medical Oncology at the City of Hope Comprehensive Cancer Center. In addition to being a devoted clinician and translational researcher, Dr. Dorff has authored more than 45 peer reviewed articles as well as 35 review articles/commentaries. Dr. Dorff serves as associate editor for Clinical Genitourinary Cancer and Seminars in Urologic Oncology. She has lectured on prostate and bladder cancer treatment nationally and internationally, and has presented her research at national meetings. Current research interests include the effects of fasting on chemotherapy side effects and cancer control and immunotherapy for prostate cancer. She has been the principal investigator for more than a dozen clinical trials, involving targeted therapy and immunotherapy, for genitourinary cancers.

Dr. Roberto Iacovelli

Dr. Roberto Iacovelli studied medicine at the “Sapienza” University of Rome, Italy. At the same University, he specialized in medical oncology and had the PhD in molecular medicine and human pathology. He had international experience as a fellow at Institute Gustave Roussy in France and as oncologist in main referral oncological centres in Italy. Currently, he is a medical oncologist at the University Hospital of Verona, Italy. His research activities focus on metastatic renal cell carcinoma, prostate and bladder cancer. His major interest is in predictive and prognostic factors in GU cancers as well as the sequence of therapy in renal cancer. He published more than one hundred papers in international peer-reviewed journals and several abstracts at international conferences on these topics. Dr Iacovelli received many national and international awards, such as the ASCO Cancer Foundation Merit Award in 2011 and the best poster award at the ESMO congress in 2012.

Dr. Phillip Koo

Phillip J. Koo, MD is the Division Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Arizona. Prior to this, he was Chief of Nuclear Medicine and Associate Professor of Radiology at the University of Colorado School of Medicine. Dr. Koo completed his transitional internship at the University of Pennsylvania Medical Center-Presbyterian, radiology residency at Pennsylvania Hospital of the University of Pennsylvania Health System, and fellowship at the Harvard Medical School Joint Program in Nuclear Medicine. He is a diplomate of both the American Board of Radiology (ABR) and American Board of Nuclear Medicine. Dr. Koo is an active member of multiple societies and serves on the Scientific Program Committee for the Radiological Society of North America, Nuclear Radiology Certifying Exam Committee for the ABR, and is the Chair of the Quality and Evidence Committee for the Society of Nuclear Medicine and Molecular Imaging (SNMMI).  He is also Chair of the Prostate Cancer Working Group at the SNMMI and was a member of the RADAR I and II working groups.   Dr. Koo has published on various topics related to radiology and nuclear medicine in multiple journals such as Radiology, Radiographics, European Journal of Nuclear Medicine and Molecular Imaging, Urology, and Journal of the American College of Radiology.  

Prof. Steven Joniau

Steven Joniau graduated in Urology in 2002 at the Catholic University of Leuven. In 2003, he was appointed full-time staff member at the Dept. of Urology, University Hospitals Leuven after a 1-year fellowship at the University Hospital of Wales, Cardiff, UK. In July 2012, he obtained his PhD in Medical Sciences entitled ‘High-risk localized prostate cancer: the role of surgery and the development of clinical outcome prediction models’. In 2013, he was appointed Assistant Professor at the Catholic University of Leuven.